Proteomics-derived Cerebrospinal Fluid Markers of Autopsy-confirmed Alzheimer's Disease

Overview

Journal Biomarkers

Specialty Biochemistry

Date 2009 Oct 30

PMID 19863188

Citations 46

Authors

Alex E Roher

Chera L Maarouf

Lucia I Sue

Yiran Hu

Jeffrey Wilson

Thomas G Beach

Affiliations

Soon will be listed here.

Abstract

The diagnostic performance of several candidate cerebrospinal fluid (CSF) protein biomarkers in neuropathologically confirmed Alzheimer's disease (AD), non-demented (ND) elderly controls and non-AD dementias (NADD) was assessed. Candidate markers were selected on the basis of initial two-dimensional gel electrophoresis studies or by literature review. Markers selected by the former method included apolipoprotein A-1 (ApoA1), haemopexin (HPX), transthyretin (TTR) and pigment epithelium-derived factor (PEDF), while markers identified from the literature included Abeta1-40, Abeta1-42, total tau, phosphorylated tau, alpha-1 acid glycoprotein (A1GP), haptoglobin, zinc alpha-2 glycoprotein (Z2GP) and apolipoprotein E (ApoE). Ventricular CSF concentrations of the markers were measured by enzyme-linked immunosorbent assay (ELISA). The concentrations of Abeta1-42, ApoA1, A1GP, ApoE, HPX and Z2GP differed significantly among AD, ND and NADD subjects. Logistic regression analysis for the diagnostic discrimination of AD from ND found that Abeta1-42, ApoA1 and HPX each had significant and independent associations with diagnosis. The CSF concentrations of these three markers distinguished AD from ND subjects with 84% sensitivity and 72% specificity, with 78% of subjects correctly classified. By comparison, using Abeta1-42 alone gave 79% sensitivity and 61% specificity, with 68% of subjects correctly classified. For the diagnostic discrimination of AD from NADD, only the concentration of Abeta1-42 was significantly related to diagnosis, with a sensitivity of 58%, specificity of 86% and 86% correctly classified. The results indicate that for the discrimination of AD from ND control subjects, measurement of a set of markers including Abeta1-42, ApoA1 and HPX improved diagnostic performance over that obtained by measurement of Abeta1-42 alone. For the discrimination of AD from NADD subjects, measurement of Abeta1-42 alone was superior.

Citing Articles

Apolipoprotein E Induces Lipid Accumulation Through Dgat2 That Is Prevented with Time-Restricted Feeding in .

C M Moraes R, Roth J, Mao H, Crawley S, Xu B, Watson J Genes (Basel). 2024; 15(11).

PMID: 39596576 PMC: 11594465. DOI: 10.3390/genes15111376.

Transcriptome analysis of the aged SAMP8 mouse model of Alzheimer's disease reveals novel molecular targets of formononetin protection.

Liu B, Cui D, Liu J, Shi J Front Pharmacol. 2024; 15:1440515.

PMID: 39234102 PMC: 11371586. DOI: 10.3389/fphar.2024.1440515.

Amyloid β Proteoforms Elucidated by Quantitative LC/MS in the 5xFAD Mouse Model of Alzheimer's Disease.

Kandi S, Cline E, Rivera B, Viola K, Zhu J, Condello C J Proteome Res. 2023; 22(11):3475-3488.

PMID: 37847596 PMC: 10840081. DOI: 10.1021/acs.jproteome.3c00353.

Apolipoprotein E in lipid metabolism and neurodegenerative disease.

Yang L, March Z, Stephenson R, Narayan P Trends Endocrinol Metab. 2023; 34(8):430-445.

PMID: 37357100 PMC: 10365028. DOI: 10.1016/j.tem.2023.05.002.

Sex-Specific Multiparameter Blood Test for the Early Diagnosis of Alzheimer's Disease.

Cho H, Schulz P, Venkataraman L, Caselli R, Sierks M Int J Mol Sci. 2022; 23(24).

PMID: 36555310 PMC: 9779188. DOI: 10.3390/ijms232415670.

References

Davidsson P, Folkesson S, Christiansson M, Lindbjer M, Dellheden B, Blennow K . Identification of proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing as a prefractionation step followed by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionisation mass spectrometry. Rapid Commun Mass Spectrom. 2002; 16(22):2083-8. DOI: 10.1002/rcm.834. View

Gartner U, Janke C, Holzer M, Vanmechelen E, Arendt T . Postmortem changes in the phosphorylation state of tau-protein in the rat brain. Neurobiol Aging. 1999; 19(6):535-43. DOI: 10.1016/s0197-4580(98)00094-3. View

Zheng P, Luider T, Pieters R, Avezaat C, van den Bent M, Sillevis Smitt P . Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J Neuropathol Exp Neurol. 2003; 62(8):855-62. DOI: 10.1093/jnen/62.8.855. View

Luoma P . Gene activation, apolipoprotein A-I/high density lipoprotein, atherosclerosis prevention and longevity. Pharmacol Toxicol. 1997; 81(2):57-64. DOI: 10.1111/j.1600-0773.1997.tb00032.x. View

Victoroff J, Mack W, Lyness S, Chui H . Multicenter clinicopathological correlation in dementia. Am J Psychiatry. 1995; 152(10):1476-84. DOI: 10.1176/ajp.152.10.1476. View

Montine T, Kaye J, Montine K, McFarland L, Morrow J, Quinn J . Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Arch Pathol Lab Med. 2001; 125(4):510-2. DOI: 10.5858/2001-125-0510-CFATAF. View

Puchades M, Hansson S, Nilsson C, Andreasen N, Blennow K, Davidsson P . Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res. 2003; 118(1-2):140-6. DOI: 10.1016/j.molbrainres.2003.08.005. View

Vanderstichele H, De Vreese K, Blennow K, Andreasen N, Sindic C, Ivanoiu A . Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med. 2006; 44(12):1472-80. DOI: 10.1515/CCLM.2006.258. View

Jung S, Lee K, Lee J, Namkoong H, Kim H, Kim S . Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease. Neurosci Lett. 2008; 436(2):153-7. DOI: 10.1016/j.neulet.2008.03.010. View

10.

Sreekumar P, Zhou J, Sohn J, Spee C, Ryan S, Maurer B . N-(4-hydroxyphenyl) retinamide augments laser-induced choroidal neovascularization in mice. Invest Ophthalmol Vis Sci. 2008; 49(3):1210-20. DOI: 10.1167/iovs.07-0667. View

11.

Mattila K, Pirttila T, Blennow K, Wallin A, Viitanen M, Frey H . Altered blood-brain-barrier function in Alzheimer's disease?. Acta Neurol Scand. 1994; 89(3):192-8. DOI: 10.1111/j.1600-0404.1994.tb01660.x. View

12.

Kawashiri M, Zhang Y, Pure E, Rader D . Combined effects of cholesterol reduction and apolipoprotein A-I expression on atherosclerosis in LDL receptor deficient mice. Atherosclerosis. 2002; 165(1):15-22. DOI: 10.1016/s0021-9150(02)00103-x. View

13.

Mayeux R, Saunders A, Shea S, Mirra S, Evans D, Roses A . Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med. 1998; 338(8):506-11. DOI: 10.1056/NEJM199802193380804. View

14.

Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K . Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007; 13(11):1359-62. DOI: 10.1038/nm1653. View

15.

Clark C, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D . Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch Neurol. 2003; 60(12):1696-702. DOI: 10.1001/archneur.60.12.1696. View

16.

Mirra S, HEYMAN A, McKeel D, SUMI S, Crain B, Brownlee L . The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991; 41(4):479-86. DOI: 10.1212/wnl.41.4.479. View

17.

Lim A, Tsuang D, Kukull W, Nochlin D, Leverenz J, McCormick W . Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J Am Geriatr Soc. 1999; 47(5):564-9. DOI: 10.1111/j.1532-5415.1999.tb02571.x. View

18.

Dittmer S, Sahin M, Pantlen A, Saxena A, Toutzaris D, Pina A . The constitutively active orphan G-protein-coupled receptor GPR39 protects from cell death by increasing secretion of pigment epithelium-derived growth factor. J Biol Chem. 2008; 283(11):7074-81. DOI: 10.1074/jbc.M704323200. View

19.

Jellinger K . Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm (Vienna). 2002; 109(5-6):813-36. DOI: 10.1007/s007020200068. View

20.

Tapiola T, Pirttila T, Mehta P, Alafuzofff I, Lehtovirta M, Soininen H . Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease. Neurobiol Aging. 2000; 21(5):735-40. DOI: 10.1016/s0197-4580(00)00164-0. View